Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Dr Reddys Lab
Join Channel
Consolidated Standalone

Dr. Reddy's Lab

₹1256.4 2.8 | 0.2%

Market Cap ₹104835 Cr.

Stock P/E 18.8

P/B 3.4

Current Price ₹1256.4

Book Value ₹ 368.5

Face Value 1

52W High ₹1420.2

Dividend Yield 0.64%

52W Low ₹ 1074.4

Edit Ratio

Dr. Reddy's Lab Research see more...

Overview Inc. Year: 1984Industry: Pharmaceuticals & Drugs

Dr. Reddy's Laboratories Limited is an India-based pharmaceutical corporation. The Company's segments consist of Global Generics, which is engaged in production and marketing prescription and over the counter finished pharmaceutical merchandise ready for consumption by patient, marketed under a brand name (branded formulations) or as usual finished dosages with healing equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and advertising and marketing active pharmaceutical elements and intermediates for finished pharmaceutical merchandise; Proprietary Products, which focuses on studies and development of differentiated formulations and Others, which includes the Company's absolutely-owned subsidiary, Aurigene Discovery Technologies Ltd, which is a discovery stage biotechnology organisation growing novel and treatments in the fields of oncology and inflammation.

Read More..

Dr. Reddy's Lab Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Dr. Reddy's Lab Quarterly Results

#(Fig in Cr.) Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 5233 6332 6790 6315 6758 6903 7237 7114 7696 8038
Other Income 854 41 59 139 174 315 216 198 187 308
Total Income 6087 6373 6849 6454 6932 7218 7453 7311 7883 8346
Total Expenditure 4292 4433 4851 4781 4696 4894 5214 5283 5566 5962
Operating Profit 1795 1940 1997 1672 2236 2323 2239 2029 2317 2384
Interest 35 31 42 35 37 35 39 59 60 76
Depreciation 302 309 324 316 353 376 374 368 381 397
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 1459 1600 1632 1322 1846 1913 1826 1602 1877 1911
Provision for Tax 279 499 394 369 445 435 448 295 490 576
Profit After Tax 1180 1100 1238 953 1401 1478 1378 1306 1387 1336
Adjustments 9 14 6 8 4 4 3 4 6 -80
Profit After Adjustments 1189 1114 1244 960 1405 1482 1381 1310 1392 1256
Adjusted Earnings Per Share 14.3 13.4 14.9 11.5 16.9 17.8 16.6 15.7 16.7 3

Dr. Reddy's Lab Profit & Loss

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
Net Sales 13415 15023 15568 14196 14281 15448 17517 19048 21545 24670 28011 30085
Other Income 196 275 295 172 155 338 621 291 485 1056 894 909
Total Income 13611 15298 15863 14368 14436 15786 18138 19339 22030 25725 28905 30993
Total Expenditure 10165 11530 11983 11724 11930 12270 15047 15178 17778 18321 20078 22025
Operating Profit 3446 3769 3880 2644 2506 3516 3091 4161 4252 7405 8827 8969
Interest 153 109 83 63 79 89 98 97 96 143 171 234
Depreciation 648 760 939 1027 1077 1135 1163 1229 1165 1250 1470 1520
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 2646 2900 2859 1554 1350 2336 1886 2884 3061 6049 7201 7216
Provision for Tax 683 563 751 297 438 386 -140 932 879 1541 1623 1809
Profit After Tax 1963 2336 2108 1257 912 1950 2026 1952 2183 4507 5578 5407
Adjustments 0 0 23 35 34 0 0 0 0 0 0 -67
Profit After Adjustments 1963 2336 2131 1292 947 1950 2026 1952 2183 4507 5578 5339
Adjusted Earnings Per Share 23.1 27.4 25 15.6 11.4 23.5 24.4 23.5 26.2 54.1 66.9 52

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 14% 14% 13% 8%
Operating Profit CAGR 19% 28% 20% 10%
PAT CAGR 24% 42% 23% 11%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 15% 11% 17% 6%
ROE Average 22% 18% 16% 17%
ROCE Average 27% 23% 19% 18%

Dr. Reddy's Lab Balance Sheet

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Shareholder's Funds 7865 9853 12570 12262 12572 14024 15599 17642 19212 23286 28255
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 2076 1432 1069 545 2509 2200 130 630 575 128 599
Other Non-Current Liabilities 107 247 -192 -89 30 -87 -938 -827 -1083 -406 -636
Total Current Liabilities 5790 6821 6347 8420 6894 5897 7214 8104 9766 8572 9588
Total Liabilities 15838 18353 19794 21138 22004 22034 22005 25548 28470 31580 37806
Fixed Assets 4641 5377 6563 6931 6968 7191 6850 8206 8122 9219 10426
Other Non-Current Assets 871 1099 1437 4524 4537 3733 2556 2792 2561 2045 2592
Total Current Assets 10326 11877 11794 9684 10498 11110 12599 14535 17788 20316 24789
Total Assets 15838 18353 19794 21138 22004 22034 22005 25548 28470 31580 37806

Dr. Reddy's Lab Cash Flow

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Opening Cash & Cash Equivalents 520 862 540 492 378 254 223 196 1482 1485 578
Cash Flow from Operating Activities 1970 2524 3263 2144 1803 2870 2984 3570 2811 5888 4543
Cash Flow from Investing Activities -1694 -2265 -2039 -1840 -1488 -773 -492 -2266 -2639 -4137 -4028
Cash Flow from Financing Activities -24 -433 -1700 -369 -444 -2133 -2516 -30 -242 -2686 -376
Net Cash Inflow / Outflow 251 -174 -477 -65 -129 -35 -24 1275 -70 -936 139
Closing Cash & Cash Equivalent 862 583 492 378 254 223 196 1482 1485 578 711

Dr. Reddy's Lab Ratios

# Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Earnings Per Share (Rs) 23.07 27.42 24.98 15.59 11.41 23.49 24.38 23.46 26.23 54.11 66.88
CEPS(Rs) 30.68 36.34 35.72 27.55 23.97 37.17 38.38 38.23 40.24 69.12 84.51
DPS(Rs) 3.6 4 4 4 4 4 5 5 6 8 8
Book NAV/Share(Rs) 91.47 114.58 146.3 146.94 150.47 168 186.46 210.52 229.2 277.8 337.21
Core EBITDA Margin(%) 24.08 23.13 23.03 17.41 16.46 20.57 14.1 20.32 17.49 25.74 28.32
EBIT Margin(%) 20.74 19.92 18.89 11.39 10.01 15.7 11.33 15.65 14.65 25.1 26.32
Pre Tax Margin(%) 19.61 19.19 18.36 10.94 9.46 15.12 10.77 15.14 14.21 24.52 25.71
PAT Margin (%) 14.55 15.47 13.54 8.86 6.39 12.62 11.57 10.25 10.13 18.27 19.91
Cash Profit Margin (%) 19.34 20.5 19.57 16.09 13.93 19.97 18.21 16.7 15.54 23.34 25.16
ROA(%) 13.47 13.67 11.05 6.14 4.23 8.86 9.2 8.21 8.08 15.01 16.08
ROE(%) 27.88 26.63 18.95 10.2 7.4 14.75 13.76 11.82 11.93 21.36 21.76
ROCE(%) 25 22.7 19.55 9.77 8.21 13.66 11.12 15.49 14.59 26.22 26.86
Receivable days 87.97 89.72 96.43 101.86 100.33 94.98 93.92 95.74 98.6 103.01 99.54
Inventory Days 62.06 60.27 60.11 69.56 73.63 74.03 71.52 77.11 81.57 73.65 73.12
Payable days 102.27 84.85 86.14 96.95 108.04 109.69 95.02 100.14 99.98 108.07 108.56
PER(x) 22.2 25.43 24.3 33.78 36.51 23.62 25.57 38.5 32.83 17.08 18.41
Price/Book(x) 5.6 6.09 4.15 3.58 2.77 3.3 3.34 4.29 3.76 3.33 3.65
Dividend Yield(%) 0.7 0.57 0.66 0.76 0.96 0.72 0.8 0.55 0.7 0.87 0.65
EV/Net Sales(x) 3.41 4.12 3.51 3.39 2.76 3.22 3.07 3.99 3.37 3.11 3.68
EV/Core EBITDA(x) 13.28 16.42 14.08 18.22 15.71 14.13 17.41 18.29 17.08 10.35 11.66
Net Sales Growth(%) 12.78 11.99 3.63 -8.81 0.6 8.17 13.39 8.74 13.11 14.5 13.54
EBIT Growth(%) 23.35 7.5 -2.24 -45.02 -11.62 69.65 -18.18 50.23 5.93 96.1 19.07
PAT Growth(%) 28.58 19.01 -9.79 -40.35 -27.43 113.72 3.9 -3.67 11.83 106.52 23.75
EPS Growth(%) 28.28 18.87 -8.92 -37.6 -26.81 105.96 3.77 -3.79 11.83 106.27 23.6
Debt/Equity(x) 0.58 0.44 0.27 0.4 0.41 0.28 0.14 0.17 0.18 0.06 0.07
Current Ratio(x) 1.78 1.74 1.86 1.15 1.52 1.88 1.75 1.79 1.82 2.37 2.59
Quick Ratio(x) 1.37 1.36 1.46 0.81 1.1 1.31 1.26 1.23 1.3 1.8 1.92
Interest Cover(x) 18.34 27.58 35.61 25.51 18.14 27.27 20.18 30.73 32.96 43.36 43.09
Total Debt/Mcap(x) 0.1 0.07 0.06 0.11 0.15 0.08 0.04 0.04 0.05 0.02 0.02

Dr. Reddy's Lab Shareholding Pattern

# Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Promoter 26.71 26.71 26.7 26.7 26.69 26.66 26.65 26.65 26.65 26.64
FII 25.87 26.26 27.29 27.25 27 28.2 28.62 29.14 27.68 27.53
DII 25.19 24.7 23.38 23.05 21.99 21.04 18.65 18.31 20.73 21.48
Public 11.87 12.26 12.1 11.7 11.78 10.09 10.74 10.55 10.36 10.13
Others 10.37 10.08 10.53 11.3 12.54 14.02 15.33 15.35 14.59 14.22
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has delivered good profit growth of 23% CAGR over last 5 years
  • Company is almost debt free.

Cons

  • Promoter holding is low: 26.64%.
  • Debtor days have increased from 108.07 to 108.56days.
  • Stock is trading at 3.4 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Dr. Reddy's Lab News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!